Experienced in Progressive Multifocal Leukoencephalopathy

Santhosh Thyagu

Ottawa, ON, CA 
Experienced in Progressive Multifocal Leukoencephalopathy
Ottawa, ON, CA 
OverviewLocationsClinical Research

Overview

Santhosh Thyagu practices in Ottawa, Canada. Mr. Thyagu is rated as an Experienced expert by MediFind in the treatment of Progressive Multifocal Leukoencephalopathy. His top areas of expertise are Graft Versus Host Disease (GvHD), Von Gierke Disease, Acute Myeloid Leukemia (AML), Infantile Neutropenia, and Bone Marrow Transplant.

His clinical research consists of co-authoring 32 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Progressive Multifocal Leukoencephalopathy.

Gender
Male

Locations

Ottawa, ON K1H8L6, Canada
Other Locations
Mount Sinai Hospital, 600 University Avenue, Toronto, ON M5G1X5, Canada
Toronto, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Critical Care Outcomes of Patients With Hematologic Malignancy and Hematopoietic Cell Transplantation
Critical Care Outcomes of Patients With Hematologic Malignancy and Hematopoietic Cell Transplantation
Enrollment Status: Active_not_recruiting
Publish Date: November 27, 2024
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

32 Total Publications

Real-World Selection of Patients for Allogeneic HCT at a Single Centre: Lack of a Suitable Donor and Other Reasons for Not Proceeding.
Real-World Selection of Patients for Allogeneic HCT at a Single Centre: Lack of a Suitable Donor and Other Reasons for Not Proceeding.
Journal: Current oncology (Toronto, Ont.)
Published: July 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Thyagu's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile